Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Apitegromab captured on Protein A Chip can bind Cynomolgus Latent GDF-8 Protein, His Tag (Cat. No. GD8-C5243) with an affinity constant of 5.41 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal | Details |
RO-7204239 | GYM-329; RO-7204239; RG-6237; RG-70240 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal | Details |
Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | Details |
AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | Details |
KER-065 | KER-065; RKER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | Details |
HS135 | HS-135 | Phase 1 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Pulmonary Arterial Hypertension | Details |
This web search service is supported by Google Inc.